title: Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report.
abstract: Gastrinomas may occur in the pancreas, duodenum or peripancreatic lymph nodes. The gastrin overproduction leads to the Zollinger-Ellison syndrome with multiple gastric and duodenal ulcers and diarrhea. About two thirds of gastrinomas are malignant. Diagnosis is made by clinical history, gastroscopy, and measurement of serum gastrin, gastric juice pH, CT scan, endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery should always be considered if the liver is not involved. Proton pump inhibitors offer symptomatic relief. Medical therapy for tumor control includes biotherapy with alpha-interferon and somatostatin analogs yielding a response rate of about 10-15%, chemotherapy or targeted radiotherapy. We describe a patient with almost complete response on treatment with Sandostatin LAR, a long-acting somatostatin analog. In patients with metastatic gastrinomas not suitable for chemotherapy, interferon or targeted radiotherapy, single therapy with somatostatin analogs may be an alternative.
authors: Department of Endocrine Oncology, Faculty of Medicine, University of Uppsala, University Hospital, Uppsala, Sweden. dan.granberg@medsci.uu.se
authors: Dan
authors: D
authors: Granberg
authors: Hans
authors: H
authors: Jacobsson
authors: Kjell
authors: K
authors: Oberg
authors: Jörgen
authors: J
authors: Gustavsson
authors: Mikael
authors: M
authors: Lehtihet
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005260:Female; D015408:Gastrinoma / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide